I Will Continue to Post, But Not Respond
As a retired biology teacher, it is my delight to explain the biology of the Anavex molecules. I will continue to do so. I will not, however, respond to murky, lame, nebulous, or un-referenced questionings of my postings.
The following comes to mind.
The Race is about to begin. Three Anavex horses are being nudged into the starting gate, one racing against Rett Syndrome, another against Parkinson’s, and the final against Alzheimer’s — the three up-coming Anavex clinical trials.
How might this race go?
As some here have implied, all three will stumble and fall into the dirt, never approaching the finish line. The horses are weak and have no ability to run the distance. Their failures in each lane will be the end of Anavex and this board. Fortunately for those seeing this outcome, they had the good sense never to take an AVXL position. Instead, they kept warning of the impending doom of the company. They saved many from financial losses.
Or, might the race turn out as follows, in any one of these potential winnings.
The gate opens, and off they go. The Rett and Parkinson’s horses cross their finish lines first (they run on a shorter track, just 12 weeks long). The Alzheimer’s horse has to circle the track several times, a one-year trial. But it gets there safely and “wins,” too.
All three of these horses end up in the winner’s circle, and take their prizes, FDA approvals. Anavex is, so to speak, a Triple Crown winner.
And, still out in the lab “pasture” are other Anavex “horses” (molecules) of the same lineage, awaiting their race times. One, Anavex 3-71, in early “training” (lab work on rats) reveals it’s stronger and faster than Anavex 2-73, particularly for Parkinson’s.
Those of us who have taken an AVXL position have placed our bets already. We’re ready for race day. Those who see the Anavex horses as weak and lame won’t be at the track. They will read of results in the Wall Street Journal, or even perhaps on the front page of the New York Times. “New Drug Gives Solid Hope for Alzheimer’s.” “Rett Girls Can Now Be Treated.” “Parkinson’s Disease Can Now Be Fixed.”
And those who watch any of the Triple Crown races watch frequent interviews of the owners and trainers of the horses in the race. The Anavex trainers are world class. The head trainer, Dr. Missling, is top notch. I don’t expect to lose any of the three races. He doesn't enter races his horses can't win.
But after any one of those three wins, I won’t be cashing in my betting ticket for several or many years — if at all. My AVXL shares will stay in my possession while Anavex stud fees (dividends and share prices) continue to escalate.
